Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma

The rapid development of immune checkpoint blockade (ICB) therapies has revolutionized the cancer treatment landscape and brightened the long-term forecast for many cancer patients. However, the specific genomic and proteomic changes in tumors treated with different ICB treatments have yet to be ful...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Li, Creasy, Todd, Pilataxi, Fernanda, Greenlees, Lydia, Vence, Luis, Sridhar, Sriram, Streicher, Katie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015996/
https://www.ncbi.nlm.nih.gov/pubmed/34623465
http://dx.doi.org/10.1007/s00262-021-03065-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015996/
https://www.ncbi.nlm.nih.gov/pubmed/34623465
http://dx.doi.org/10.1007/s00262-021-03065-5

Ejemplares similares